Metformin Reduces Serum C-Reactive Protein Levels in Women with Polycystic Ovary Syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 10, 2003, Pages 4649-4654

  Morin Papunen, Laure ^a   Rautio, Katriina ^a   Ruokonen, Aimo ^a   Hedberg, Pirjo ^a   Puukka, Matti ^a   Tapanainen, Juha S ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIANE; DIANE-NOVA; METFORMIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN ACTIVITY; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; C-REACTIVE PROTEIN; CYPROTERONE ACETATE; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; PROGESTERONE CONGENERS;

FALLOPIA;

EID: 0242351851     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021688     Document Type: Article

References (53)

1. Dunaif A, Segal KR, Futterweit W, Dobrjansky A 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174
2. Burghen GA, Givens JR, Kitabchi AE 1980 Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50:113-116
3. Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH 1983 Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab 57:304-310
4. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW 1999 C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978
5. Festa A, D'Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM 2000 Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47
6. Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M 2002 Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 45:151
7. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N 2001 Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453-2455
8. Ridker PM, Hennekens CH, Buring JE, Rifai N 2000 C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836-843
9. Danesh J, Collins R, Appleby P, Peto R 1998 Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477-1482
10. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ 1994 Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metab Clin Exp 43:647-654
11. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK 1998 Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69:691-696
12. Nestler JE, Jakubowicz DJ 1997 Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 α activity and serum androgens. J Clin Endocrinol Metab 82:4075-4079
13. Elter K, Imir G, Durmusoglu F 2002 Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 17:1729-1737
14. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS 2000 Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 15:1266-1274
15. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM 2000 Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767-2774
16. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS 2000 Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 85:3161-3168
17. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS 2003 Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 88:148-156
18. Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD 2002 Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25:542-549
19. Campbell PJ, Gerich JE 1990 Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab 70:1114-1118
20. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A 1987 Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 65: 499-507
21. Homburg R 1996 Polycystic ovary syndrome-from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod 11:29-39
22. Ferriman D, Gallwey JD 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447
23. Jilma B, Dimberger E, Loscher I, Rumplmayr A, Hildebrandt J, Eichler HG, Kapiotis S, Wagner OF 1997 Menstrual cycle-associated changes in blood levels of interleukin-6, α1 acid glycoprotein, and C-reactive protein. J Lab Clin Med 130:69-75
24. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP 1999 Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100:717-722
25. Cushman M 2002 Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. Am J Cardiol 90:7F-10F
26. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE 1999 Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100:713-716
27. Festa A, D'Agostino Jr R, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM 2001 The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 25:1407-1415
28. Ford ES 1999 Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22:1971-1977
29. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET 2002 Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105:564-569
30. Laimer M, Ebenbichler CF, Kaser S, Sandhofer A, Weiss H, Nehoda H, Aigner F, Patsch JR 2002 Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes Relat Metab Disord 26:659-662
31. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G 2001 C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord 25:1416-1420
32. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB 1999 Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-2135
33. Lemieux I, Pascot A, Prud'homme D, Aimeras N, Bogaty P, Nadeau A, Bergeron J, Despres JP 2001 Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vase Biol 21:961-967
34. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P 2002 Differentiation between obesity and insulin resistance in the association C-reactive protein. Circulation 106:2908-2912
35. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL 2003 Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46:625-633
36. Ferri C, Bellini C, Desideri G, Di Francesco L, Baldoncini R, Santucci A, De Mattia G 1995 Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes 44:431-436
37. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR 1990 Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33:306-310
38. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis C, 2001 Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86:4666-4673
39. Pasceri V, Willerson JT, Yeh ET 2000 Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165-2168
40. Blake GJ, Ridker PM 2002 Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252:283-294
41. Vessey MP, Villard-Mackintosh L, McPherson K, Yeates D 1989 Mortality among oral contraceptive users: 20 year follow up of women in a cohort study. BMJ 299:1487-1491
42. Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C, Thomas S, Mann R 1999 Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 318:1579-1583
43. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC 2001 Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 86:550-556
44. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H 2001 Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85:619-625
45. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G 1999 Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353:1649-1652
46. Chasan-Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA, Spiegelman D, Manson JE 1997 A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 20:330-335
47. Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Hennekens CH, Speizer FE 1992 Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 35:967-972
48. Wynn V, Adams PW, Godsland I, Melrose J, Niththyananthan R, Oakley NW, Seed M 1979 Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1:1045-1049
49. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V 1990 The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323:1375-1381
50. Korytkowski M, Mokan M, Horwitz M, Berga S 1995 Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:3327-3334
51. Nader S, Riad-Gabriel MG, Saad MF 1997 The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 82:3074-3077
52. Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO 1998 Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 13:2706-2711
53. Prelevic GM, Wurzburger MI, Trpkovic D, Balint-Peric L 1990 Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome. Gynecol Endocrinol 4:157-168